SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl is drawing attention after a strong Q3 earnings report, with traders highlighting better-than-expected results, growth in assets and fee-related earnings, and managements positive outlook on dividend coverage and future fees. Many expect sentiment to improve, while others remain cautious about private-credit redemptions and point to put-heavy options activity.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Discussion centers on speculation that Middle East LNG disruptions and shipping risks could strengthen demand and pricing for U.S. exporters, including NextDecades Rio Grande project. Bulls point to the projects progress and future capacity, while skeptics emphasize that NEXT has no current LNG production or revenue and still faces construction, financing, and competition risks.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its choppy, weak trading and repeated difficulty holding above the eight-cent area, with traders also linking pressure to broader crypto-market declines. The conversation is split between bearish frustration over losses and calls to buy the dip or hold for a recovery.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Traders are focused on Zebecs payroll and payments expansion, including MoneyGram/Stellar links and Robinhood Chain support, as potential adoption drivers. Bullish holders are accumulating, while skeptics question whether actual usage will translate into ZBCN demand given its weak, uneven price performance.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic investment is drawing attention amid IPO-filing and valuation chatter, with bullish traders viewing the stake as a potential source of value. Others question whether it can offset Zooms modest core-business growth and competitive pressures; discussion also references recent earnings beats and raised full-year guidance.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths order for more than 50,000 optical assemblies for defense-drone cameras is drawing attention to its counter-drone and thermal-optics business. Bulls see room for recurring demand and further defense orders, while skeptics want earnings and revenue to confirm the growth story; broad market and defense-sector weakness have also weighed on the shares.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention for its steep, prolonged selloff and repeated tests of key support, with traders debating whether the weakness reflects valuation concerns, insider selling and a broader defense-sector pullbackor an oversold buying opportunity. Optimists point to contract wins, growth prospects and analyst upgrades, while skeptics say positive developments have not reversed the downtrend ahead of upcoming earnings.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Galaxy Digitals adoption of Skys yield-bearing stablecoin for its treasury and lending collateral, alongside a reported purchase of SKY, is driving discussion of growing institutional interest in the Sky ecosystem. Traders are watching for a breakout, while others see the recent pullback as a warning and question whether the rally can hold.

Direxion Shares ETF Trust - Direxion Daily GOOGL Bull 2X ETF

Direxion Daily GOOGL Bull 2X Shares ETF

Alphabets sharp post-earnings selloff is driving attention to GGLL, with many traders buying the dip for a rebound while others warn that market weakness and deteriorating technicals could bring further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Equity

Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

Surrozen (NASDAQ:SRZN) CEO Craig Parker Sells 4,524 Shares

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) CEO Craig Parker sold 4,524 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total transaction of $150,784.92. Following the completion of the transaction, the chief...

Surrozen (NASDAQ:SRZN) COO Charles Williams Sells 2,036 Shares

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) COO Charles Williams sold 2,036 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $67,859.88. Following the transaction, the chief operating officer...

Yang Li Sells 1,584 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) VP Yang Li sold 1,584 shares of the business's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $33.33, for a total transaction of $52,794.72. Following the completion of the transaction, the vice president directly...

Surrozen (SRZN) Projected to Post Quarterly Earnings on Friday

Surrozen (NASDAQ:SRZN) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...

Surrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short Interest

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 434,571 shares, an increase...

Surrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of "Moderate Buy" from Brokerages

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and...

Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?

Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?

Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Surrozen (NASDAQ:SRZN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Surrozen from a "sell" rating to a "hold" rating in a report on Saturday...

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Surrozen Inc

Bullish Sentiment

<ul class="summary-bullets"><li>INDP’s rally followed a $24 million share sale, with proceeds potentially supporting early research into a sleep-related device.</li><li>Former biotech CYPH gained as its Zcash mining operation added 3,023 ZEC to its treasury.</li><li>MNOV completed patient visits in the blinded portion of its ALS trial, while a favorable FDA advisory panel vote lifted attention on GRAL’s Galleri test.</li></ul>Moderna, Inc. (MRNA) is on track to become September’s second-best performer in the S&amp;P 500, but five smaller stocks have delivered even larger gains this month, driven by developments ranging from an impending ALS trial readout to a cancer-test regulatory review, and, in one case, a Zcash strategy.<a href="https://stocktwits.com/symbol/MRNA">Moderna (MRNA)</a> is up about 39% so far this month. Among stocks with market caps above $100 million,&nbsp;<a href="https://stocktwits.com/symbol/INDP">Indaptus Therapeutics (INDP)</a> has surged about 249%, followed by&nbsp;<a href="https://stocktwits.com/symbol/CYPH">Cypherpunk Technologies (CYPH)</a> at 124%,&nbsp;<a href="https://stocktwits.com/symbol/MNOV">MediciNova (MNOV)</a> at 85%,&nbsp;<a href="https://stocktwits.com/symbol/GRAL">GRAIL (GRAL)</a> at 58% and&nbsp;<a href="https://stocktwits.com/symbol/SRZN">Surrozen (SRZN)</a> at 53%.&nbsp;<img src="https://news.stocktwits-cdn.com/mrna_rally_c347f1f47e.png" alt="mrna rally.png"><h2 class="st-heading-2">Moderna’s Phase 3 Win Faces Its Next Test&nbsp;</h2>The foundation for Moderna’s rally was laid in August, when the company and partner Merck announced that their Phase 3 trial of personalized cancer vaccine Intismeran autogene plus Keytruda met its primary endpoint in patients whose melanoma had been surgically removed. The companies also reported success on a key secondary endpoint, but have not yet presented the detailed trial results.This week, Moderna gave investors a date for that closer examination: the Phase 3 findings will be presented at a Presidential Symposium on Oct.24 during the European Society for Medical Oncology congress.&nbsp;At a recent Bernstein healthcare conference, CEO Stéphane Bancel said, “Moderna has been, since day one, an mRNA platform company,” calling intismeran “only our first oncology product.” Moderna and Merck have nine studies ongoing, he said, but they still must test the potential for the treatment to work in other cancers. Chief development officer David Berman said he was “very confident that we have a strong case for approval” in melanoma.&nbsp;Stocktwits sentiment for MRNA was ‘extremely bullish’ a month ago, slipped to ‘bearish’ a week ago and recovered to ‘bullish’ on Thursday before returning to ‘extremely bullish’ in the latest reading. Over the month, message volume rose 336% and the ticker’s watcher base grew 5%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_b81951629d.png" alt="mrna ss.png" width="645" height="355"><figcaption>MRNA sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">INDP Surges On $24M Financing&nbsp;</h2>Indaptus Therapeutics has delivered the largest September gain of the group as investors assess a possible new direction for the company. Last month, Indaptus said it had stopped enrolling patients in its Decoy20 cancer study and had no active clinical development programs. However, earlier this month the company announced a financing deal and disclosed plans to explore a neurotechnology device for certain sleep-related conditions, with a potential future FDA submission in view.&nbsp;The firm also agreed to sell 20.3 million shares at $1.18 each in a private placement expected to raise about $24 million. The price was about 1% above the deal’s Nasdaq pricing benchmark, though about 3% below INDP’s close before the agreement.&nbsp;Stocktwits sentiment for INDP shifted from ‘bullish’ a month ago to ‘bearish’ a week ago and remained ‘bearish’ in the latest reading. The ticker’s watcher base edged up 0.3% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/indp_ss_9ade02b797.png" alt="indp ss.png" width="640" height="344"><figcaption>INDP sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">CYPH Rallies As Zcash Mining Adds To Treasury&nbsp;</h2>Cypherpunk Technologies, previously known as Leap Therapeutics, changed its name and ticker last year to reflect a Zcash-based strategy. Its remaining cancer-drug operations sit within a Leap Therapeutics unit.&nbsp;Cypherpunk announced this week the launch of a 4.2 GSol/s Zcash mining fleet and said the operation had generated 3,023.13 ZEC in its first weeks, with the coins added to its treasury. The company had previously reported holdings of 323,394.38 ZEC as of Aug. 11.&nbsp;Stocktwits sentiment for CYPH remained ‘extremely bullish’ throughout the past month, though its score eased from (91/100) to (79/100). Over the same period, message volume surged 5,200%, and the ticker’s watcher base grew 4%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/cyph_ss_d24fe58448.png" alt="cyph ss.png" width="629" height="343"><figcaption>CYPH sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">MNOV Gains Ahead Of Year-End ALS Results&nbsp;</h2>MediciNova has climbed as investors look ahead to results from its Phase 2b/3 Combat-ALS trial of MN-166, or ibudilast. On Thursday, the company said the final patient had completed the last visit in the trial’s blinded portion. The study randomized 234 participants, and MediciNova expects to report topline findings by year-end. Its primary endpoint combines measures of function and survival. CEO Yuichi Iwaki said the company’s focus had shifted to “database lock and rigorous analysis of the study data.”&nbsp;Stocktwits sentiment for MNOV rose from ‘bullish’ a month ago to ‘extremely bullish’ a week ago, but has since fallen back through ‘bullish’ to ‘bearish’ in the latest reading. The ticker’s watcher base grew 0.6% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/mnov_ss_84eff47815.png" alt="mnov ss.png" width="646" height="353"><figcaption>MNOV sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">GRAIL’s Galleri Wins A Favorable Panel Vote&nbsp;</h2>GRAIL’s September catalyst was a recent FDA advisory committee meeting on Galleri, its blood test intended to detect signals associated with multiple cancers in adults aged 50 and older. The panel&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gral-s-galleri-cancer-test-clears-fda-panel-safety-vote-splits-on-effectiveness/cZM4avyRBBh">voted</a> 10-0 in support of the test’s safety, 6-4 on effectiveness, and 7-2, with one abstention, that its benefits outweighed its risks. Galleri is intended to be used alongside existing recommended cancer screenings, not as a replacement.&nbsp;The favorable votes advanced GRAIL’s case, but the FDA has yet to decide whether to approve the test and is not bound by the panel’s recommendation.Stocktwits sentiment for GRAIL shifted from ‘bullish’ a month ago to ‘bearish’ a week ago, then surged to ‘extremely bullish’ in the latest reading. The ticker’s watcher base grew 1% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/grail_ss_65154b4dbf.png" alt="grail ss.png" width="651" height="351"><figcaption>GRAL sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">SRZN’s Eye-Drug Filing Sets Up Clinical Trial&nbsp;</h2>Surrozen submitted an investigational new drug application earlier this month for SZN-8141, an experimental antibody for diabetic macular edema. The treatment will combine activation of the Wnt pathway with inhibition of VEGF, a target already used in retinal-disease treatments. The company aims to begin an early-stage study by year-end, subject to regulatory clearance, and expects initial data in the second half of 2027.&nbsp;Stocktwits sentiment for SRZN moved from ‘neutral’ a month ago to ‘bullish’ a week ago, dipped to ‘bearish’ on Thursday, then rebounded to ‘extremely bullish’ in the latest reading. Over the month, message volume rose 50%, and the ticker’s watcher base edged up 0.1%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/srzn_ss_4bd078b953.png" alt="srzn ss.png" width="633" height="348"><figcaption>SRZN sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure>Year to date, MRNA has surged about 561%, followed by CYPH at 252%, MNOV at 102%, SRZN at 49%, GRAL at 46% and INDP at 37%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bb-stock-qnx-royalties-star-of-the-show-president-holdings-revealed/cZMarhGRBad">BB Stock Eyes Best Week In 3 Months As QNX Royalties Become ‘Star Of The Show’ — President’s Holdings Revealed&nbsp;</a>

In this photo illustration, the American pharmaceutical and biotechnology company Moderna logo is displayed on a smartphone screen. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Cypherpunk Technologies Inc.

GRAIL Inc.

iShares Biotechnology ETF

Indaptus Therapeutics Inc

Medicinova Inc

Moderna Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$29.04
Prev Close	$29.46
Open	$29.32
Dividend Yield	0.00%
50-Day Moving Average	$24.31
Beta	0.79
Avg. Volume	893,620.75
PE Ratio	-0.66

52-Week High	$37.83
52-Week Low	$11.39
Market Capitalization	$341.32M
EPS (Annual)	-$32.37
Price to Book	-1.56
Revenue Per Employee	$79,022.73

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRZN Fundamentals